🚀 VC round data is live in beta, check it out!
Diagnos Valuation Multiples
Discover revenue and EBITDA valuation multiples for Diagnos and similar public comparables like NanoRepro, CurveBeam AI, EBM Technologies, Impedimed and more.
Diagnos Overview
About Diagnos
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
Founded
1996
HQ
Employees
15
Website
Financials (FY)
EV
$21M
Diagnos Financials
Diagnos reported last fiscal year revenue of $76K and negative EBITDA of ($3M).
In the same fiscal year, Diagnos generated ($689K) in gross profit, ($3M) in EBITDA losses, and had net loss of ($3M).
Revenue (LTM)
Diagnos P&L
In the most recent fiscal year, Diagnos reported revenue of $76K and EBITDA of ($3M).
Diagnos expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $76K | XXX | XXX | XXX |
| Gross Profit | — | XXX | ($689K) | XXX | XXX | XXX |
| Gross Margin | — | XXX | (909%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3434%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (3672%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($3M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (4096%) | XXX | XXX | XXX |
| Net Debt | — | — | $2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Diagnos Stock Performance
Diagnos has current market cap of $22M, and enterprise value of $21M.
Market Cap Evolution
Diagnos' stock price is $0.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21M | $22M | 0.2% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDiagnos Valuation Multiples
Diagnos trades at 272.7x EV/Revenue multiple, and (7.9x) EV/EBITDA.
EV / Revenue (LTM)
Diagnos Financial Valuation Multiples
As of April 18, 2026, Diagnos has market cap of $22M and EV of $21M.
Equity research analysts estimate Diagnos' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diagnos has a P/E ratio of (7.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $22M | XXX | $22M | XXX | XXX | XXX |
| EV (current) | $21M | XXX | $21M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 272.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (7.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (7.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (30.0x) | XXX | XXX | XXX |
| P/E | — | XXX | (7.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Diagnos Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Diagnos Margins & Growth Rates
Diagnos' revenue in the last fiscal year declined by (14%).
Diagnos' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Diagnos Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (14%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3434%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 9% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 2763% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Diagnos Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Diagnos | XXX | XXX | XXX | XXX | XXX | XXX |
| NanoRepro | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| EBM Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Impedimed | XXX | XXX | XXX | XXX | XXX | XXX |
| SenzaGen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diagnos M&A Activity
Diagnos acquired XXX companies to date.
Last acquisition by Diagnos was on XXXXXXXX, XXXXX. Diagnos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Diagnos
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDiagnos Investment Activity
Diagnos invested in XXX companies to date.
Diagnos made its latest investment on XXXXXXXX, XXXXX. Diagnos invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Diagnos
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Diagnos
| When was Diagnos founded? | Diagnos was founded in 1996. |
| Where is Diagnos headquartered? | Diagnos is headquartered in Canada. |
| How many employees does Diagnos have? | As of today, Diagnos has over 15 employees. |
| Is Diagnos publicly listed? | Yes, Diagnos is a public company listed on Toronto Stock Exchange. |
| What is the stock symbol of Diagnos? | Diagnos trades under ADK ticker. |
| When did Diagnos go public? | Diagnos went public in 2000. |
| Who are competitors of Diagnos? | Diagnos main competitors are NanoRepro, CurveBeam AI, EBM Technologies, Impedimed. |
| What is the current market cap of Diagnos? | Diagnos' current market cap is $22M. |
| What is the current revenue of Diagnos? | Diagnos' last fiscal year revenue is $76K. |
| What is the current EV/Revenue multiple of Diagnos? | Current revenue multiple of Diagnos is 272.7x. |
| Is Diagnos profitable? | No, Diagnos is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.